Understanding and treating long COVID

Dr. Paul Marik Dr. Mobeen Syed



How the NIH defines long COVID

Large study provides scientists with deeper insight into long COVID symptoms

doi:10.1001/jama.2023.8823

The team found that 37 symptoms were substantially more likely to occur in people who had been infected with COVID-19.

Of these, 12 in particular best distinguish those with and without long COVID:

- or mental activity)
- Fatigue
- Brain fog
- Dizziness
- Gut symptoms
- Heart palpitations
- Sexual problems
- Change in smell or taste
- Thirst
- Chronic cough
- Chest pain

• Post-exertional malaise (the worsening of symptoms after physical

• Abnormal movements such as muscle twitching or jerking

How FLCCC defines long COVID

From the I-RECOVER protocol

https://covid19criticalcare.com/protocol/i-recover-long-covid-treatment/

The clinical signs and symptoms can be grouped into the following clusters. The reason for this grouping is to allow organ-specific targeted therapy or individualized therapy:

 Respiratory: shortness of breath, congestion, persistent cough, etc.
Neurological/psychiatric: brain fog, malaise, tiredness, headaches, migraines, depression, inability to focus or concentrate, altered cognition, insomnia, vertigo, panic attacks, tinnitus, anosmia, phantom smells, etc.
Musculoskeletal: myalgias, fatigue, weakness, joint pains, inability to exercise, post-exertional malaise, inability to perform normal activities of daily life

4. Cardiovascular: Palpitations, arrhythmias, Raynaud-like syndrome, hypotension, and tachycardia on exertion

Autonomic: Postural tachycardia syndrome (POTs), abnormal sweating
Gastrointestinal disturbance: anorexia, diarrhea, bloating, vomiting,


6. Gastrointestinal disturbance: a nausea, etc.

7. Dermatologic: itching, rashes, dermatographia

8. Mucus membranes: running nose, sneezing, burning and itchy eyes

LONG COVID AFTER OMICRON VS. ITS ANCESTORS LONG COVID AFTER REINFECTION











STUDY (HAEMATOLOGY PATIENTS) MORTALITY REDUCED IN OMICRON ERA LONG COULD REDUCED IN OMICRON ERA





MORTAUTY 90 DAYS ATTRIBUTED TO 42% LONG COUID RISK 46%

STUDY (CANCER PATIENTS: VACCINATED AND UNVACCINATED)



Lancet Oncol. 2023 Apr; 24(4): 335-346.

Published online 2023 Mar 7. doi: 10.1016/S1470-2045(23)00056-6


SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry

PMCID: PMC9991062 PMID: 36898391

MD,^{ar} <u>Claudia A M Fulgenzi</u>, MD,^{a,o} <u>Antonio D'Alessio</u>, MD,^{a,n} <u>Isabel Ruiz-Camps</u>, PhD,^{ag} <u>Nadia Saoudi-Gonzalez</u>, MD,^c <u>David Garcia Illescas</u>, MD,^c <u>Irene Medina</u>, MD,^{ah} <u>Laura Fox</u>, MD,^{ah} <u>Alessandra Gennari</u>, MD,^{h,x} <u>Juan Aguilar-Company</u>, MD,^{c,ag} <u>David J Pinato</u>, PhD,^{a,h} and OnCovid study group, on behalf of the

Findings

At the follow-up update on June 20, 2022, 1909 eligible patients, evaluated after a median of 39 days (IQR 24–68) from COVID-19 diagnosis, were included (964 [50.7%] of 1902 patients with sex data were female and 938 [49.3%] were male). Overall, 317 (16.6%; 95% CI 14.8–18.5) of 1909 patients had at least one sequela from COVID-19 at the first oncological reassessment. The prevalence of COVID-19 sequelae was highest in the pre-vaccination phase (191 [19.1%; 95% CI 16.4–22.0] of 1000 patients). The prevalence was similar in the alpha-delta phase (110 [16.8%; 13.8-20.3] of 653 patients, p=0.24, but significantly lower in the omicron phase (16 [6.2%; 3.5–10.2] of 256 patients, p<0.0001). In the alpha-delta phase, 84 (18.3%; 95% CI 14.6-22.7) of 458 unvaccinated patients and three (9.4%; 1.9-27.3) of 32 unvaccinated patients in the omicron phase had sequelae. Patients who received a booster and those who received two vaccine doses had a significantly lower prevalence of overall COVID-19 sequelae than unvaccinated or partially vaccinated patients (ten [7·4%; 95% CI 3·5–13·5] of 136 boosted patients, 18 [9·8%; 5·8–15·5] of 183 patients who had two vaccine doses vs 277 [18.5%; 16.5–20.9] of 1489 unvaccinated patients, p=0.0001), respiratory sequelae (six [4·4%; 1·6–9·6], 11 [6·0%; 3·0–10·7] vs 148 [9·9%; 8·4–11·6], p=0·030), and prolonged fatigue (three [2·2%; 0·1–6·4], ten [5·4%; 2·6–10·0] vs 115 [7·7%; 6·3–9·3], p=0·037).



Post-acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

MTHFR and the possibility of blood clotting









/S

OH NH2





References

Factors associated with psychiatric outcomes and coping in Long COVID | Nature **Mental Health** https://www.nature.com/articles/s44220-023-00064-6

Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection -PubMed https://pubmed.ncbi.nlm.nih.gov/37278994/

Mortality and burden of post-COVID-19 syndrome have reduced with time across SARS-CoV-2 variants in haematology patients - PubMed https://pubmed.ncbi.nlm.nih.gov/36861893/

SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry - PMC https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991062/

Post-acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection by Viral Variant and Vaccination Status: A Multicenter **Cross-sectional Study | Clinical Infectious Diseases | Oxford Academic** https://academic.oup.com/cid/advancearticle/doi/10.1093/cid/ciad143/7076063?login=false

the UK - Office for National Statistics

https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditions and diseases/bulletins/newonsetselfreportedlongcovidaftercoronaviruscovid19reinfection intheuk/23february2023

PMC

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212672/

New-onset, self-reported long COVID after coronavirus (COVID-19) reinfection in

Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2 -